Loading...
Loading...
Ranked by Compass Score · 20 companies · Updated July 25, 2026
Biotech draws a particular kind of investor: someone who got burned once, swore off it, then got tempted back by a headline about CRISPR or GLP-1 follow-ons. The sector runs on hype cycles, and most money chases whatever the last FDA approval blessed. The obvious plays get crowded fast, valuations detach from the underlying science, and the exit, when it comes, is uglier than expected.
The Compass Score cuts through that by treating biotech the way you'd treat any high-variance bet: systematically. Pipeline depth, balance sheet durability, clinical-stage risk weighting, and a few factors the consensus models tend to discount. Genomics in particular has moved from research curiosity to commercial reality faster than most analysts revised their models, which means the mispricing now sits in companies that have cleared the hard science but haven't yet cleared the market's skepticism. Those are the positions worth examining.
Get our top Biotech & Genomics ideas, free
The Alexandria e-letter delivers our highest-conviction picks, earnings intelligence, and contrarian calls twice a week. Join free.
Free forever. Unsubscribe anytime. We never share your email.
Higher Compass Scores reflect where fundamentals, momentum, and forward catalysts align. Tap any company for the full breakdown.
Standout: Market Position (86/100) · Direction: Accumulate · $27.6B
Standout: Market Position (97/100) · Direction: Accumulate · $1.07T
Standout: Revenue Growth (98/100) · Direction: Accumulate · $4.8B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $8.6B
Standout: Momentum (87/100) · Direction: Accumulate · $9.7B
Standout: Theme Purity (99/100) · Direction: Accumulate · $36.3B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.6B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.2B
Standout: Theme Purity (99/100) · Direction: Accumulate · $4.6B
Standout: Moat (90/100) · Direction: Accumulate · $68.8B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.2B
Standout: Theme Purity (99/100) · $121.2B
Standout: Profitability (78/100) · Direction: Accumulate · $9.9B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $7.4B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.6B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $57.1B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.3B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $4.3B
Standout: Theme Purity (99/100) · Direction: Accumulate · $126.6B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $521M
By Alexandria's Compass Score, DexCom Inc. (NASDAQ:DXCM) currently ranks highest among Biotech & Genomics names with a score of 91/100 (True North). Compass Scores are recomputed weekly across eight factors, so rankings shift as the fundamentals do.
Every company is scored 1-100 on eight weighted factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The composite is percentile-normalized into a Compass Score and a tier from True North to Avoid. It is a contrarian lens that rewards what the crowd overlooks rather than what is already priced in.
A high Compass Score reflects where fundamentals, momentum, and forward catalysts align. It is research, not investment advice. Use the ranking as a starting point, then read each company's full Compass Direction analysis before making any decision.
Get the contrarian edge, free
Join the Alexandria e-letter for top-rated stocks, earnings intelligence, and the take the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Compass Scores are proprietary editorial research generated by Alexandria's analysis engine from publicly available data. They are one data point among many and do not constitute investment advice or a recommendation regarding any security. Rankings update weekly and may change.